Cogstate Limited

Cogstate Limited

COGZF
Cogstate LimitedUS flagOther OTC
1.70
USD
-0.15
- -
291.37MMarket Cap
Cogstate Limited
COGZF
(Other OTC)

Recent

price

1.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.12
0.13
0.16
0.15
0.13
0.12
0.18
0.24
0.25
0.18
0.15
0.19
0.26
0.23
0.25
0.3
Revenue per Share
0.02
-0.01
0.03
-0.02
-0.04
-0.04
0.02
-0.01
- -
-0.02
-0.01
0.03
0.04
0.02
0.03
0.06
Basic EPS, GAAP
0.01
0.01
0.01
-0.03
-0.05
-0.04
0.01
0.01
-0.02
-0.02
-0.02
-0.02
-0.02
-0.01
-0.01
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.07
0.08
0.12
0.09
0.12
0.07
0.09
0.09
0.11
0.09
0.11
0.14
0.19
0.21
0.23
0.25
Book Value per Share
0.08
0.09
0.1
0.08
0.11
0.07
0.09
0.09
0.08
0.04
0.06
0.08
0.13
0.15
0.18
0.22
Tangible Book Value per Share
67
68
75
77
91
100
111
114
115
119
159
170
173
173
172
171
Basic Weighted Avg Shares
8
9
12
11
12
12
20
27
29
22
24
33
45
40
43
51
Sales/Revenue/Turnover
2.82
-2.68
11.94
-19.62
-38.89
-26.96
2.57
-1.41
0.63
-26.8
-8.13
11.71
24.14
5.57
14.21
21.25
Operating Margin (%)
- -
- -
1
1
1
1
1
1
1
- -
2
2
2
3
3
3
Depreciation Expense
1
-1
3
-2
-4
-4
2
-1
-1
-2
-1
5
8
4
5
10
Net Income, GAAP
- -
- -
12.19
- -
- -
- -
- -
- -
632.79
- -
- -
10.09
29.67
- -
23.26
27.06
Effective Tax Rate (%)
17.27
-10.4
20.41
-15.7
-31.7
-31.49
9.69
-2.36
-1.95
-11.43
-5.56
16.01
16.72
8.82
12.55
19.97
Profit Margin (%)
3
4
5
5
8
6
6
7
6
- -
3
15
24
26
31
37
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
1
- -
- -
- -
LT Debt
6
7
10
8
12
8
10
11
12
10
16
22
33
38
41
48
Total Equity
- -
- -
14.98
- -
- -
- -
- -
- -
-8.59
- -
- -
15.39
26.4
- -
11.89
17.35
Return on Invested Capital (%)
- -
- -
35.58
- -
- -
- -
- -
- -
-8.56
- -
- -
22.4
25.58
- -
14.42
24.41
Return on Capital (%)
34.32
-17.82
34.94
-22.39
-41.98
-43.92
23.24
-6.37
-5.03
-21.12
-9.2
25.74
26.8
10.33
14.52
24.61
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.81%
25.26%
17.05%
Free Cash Flow
-35.55%
4.7%
62.79%
Net Income, GAAP
-36.75%
-73.54%
86.15%
Sales/Revenue/Turnover
17.86%
17.98%
17%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
40
2024
- -
- -
- -
- -
43
2025
- -
- -
- -
- -
51

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.02
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
0.06

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
Cogstate Limited (OTC: COGZF) provides computerized cognitive assessments for clinical trials, clinical practice, and healthcare settings worldwide. The company offers a suite of proprietary, validated digital tests including the Cogstate Brief Battery for screening mild cognitive impairment and Alzheimer's disease; the Cogstate Alzheimer's Battery for early detection and monitoring of Alzheimer's pathology; computerized neuropsychological tests for schizophrenia and other CNS disorders; and the Cognigram platform for remote cognitive screening in primary care. These products support pharmaceutical companies, contract research organizations, healthcare providers, and academic researchers in measuring cognitive function objectively and reliably; services encompass test administration, data management, and regulatory-compliant reporting. Founded in 1999 and headquartered in Melbourne, Australia, Cogstate operates primarily in North America, Europe, and Australia, with a focus on central nervous system therapeutics and neurology segments targeting biotech, pharma, and telehealth markets.

Company News

APIChat
  • Cogstate Limited (COGZF) Q2 2026 Earnings Call Transcript

  • Cogstate Limited (COGZF) FY 2025 Earnings Call Transcript

  • Cogstate Limited (COGZF) Q2 2025 Earnings Call Transcript

  • Cogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical Officer

  • Cogstate Limited (COGZF) Q4 2024 Earnings Call Transcript

  • Cogstate Limited (COGZF) Q4 2022 Earnings Call Transcript

  • Cogstate Limited (COGZF) CEO Brad O'Connor on Q4 2022 Results - Earnings Call Transcript